Suppressive Antibiotic Therapy for Endocarditis

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Oct 24, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating the use of long-term antibiotic therapy for patients with endocarditis, a serious infection of the heart that can be particularly dangerous for older individuals or those with existing health issues. The study aims to understand how this extended treatment affects patient survival over six months and one year. It also looks at how the treatment is given, any side effects, and the reasons for patients' deaths. This information is important because patients with infected heart devices often cannot undergo risky surgeries, so finding a safe and effective way to manage their infection is crucial.

To be eligible for this study, participants must be at least 18 years old, have received suppressive antibiotic therapy for endocarditis since January 2016, and agree to allow their data to be used for research. They cannot have declined to participate in the study before starting the antibiotic treatment. If you or a loved one qualifies for this trial, you can expect to contribute to valuable research that may help improve treatment options for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Major subject (≥18 years old)
• • Subject having benefited from suppressive antibiotic therapy after collegial decision in CPR Endocarditis during the period from January 1, 2016 to January 31, 2023
• • Subject not opposing the reuse of their data for the purposes of this research.
• Exclusion criteria:
• • Subject having expressed opposition to participating in the study
• • Death or loss of sight of the patient before initiation of suppressive antibiotic therapy.